Franck Perraudin: Lp(a) Lowering Alone May Not Be Enough
Franck Perraudin, VP – Cardiovascular TA Head International Commercial and Launch Strategy at Novartis, shared a post on LinkedIn:
“The Phase 3 HORIZON Trial showed that reductions in Lipoprotein(a) (Lp(a)) did not meet its primary endpoint of reducing a composite of cardiovascular death.
This is for sure a set back, a deception for ASCVD patients with elevated Lp(a) and yet it need to be regarded as a scientific progress in understanding human biology and cardiovascular risk factors.
Lp(a) remains a well-established, inherited cardiovascular risk factor.
For patients, the message is clear: cardiovascular risk remains multifactorial, and optimizing LDL‑C and comorbidities is more important than ever.
- Lp(a) lowering alone may not be enough — residual risk from LDL‑C, inflammation, diabetes, hypertension, and obesity still drives events.
- LDL‑C long term management and optimization remains the strongest proven lever for reducing ASCVD risk.
- Comorbidity control (diabetes, blood pressure, weight, kidney disease, smoking) is decisive for long‑term outcomes.
The Opportunity Ahead:
Pelacarsen’s results don’t close the door on Lp(a) therapies — they sharpen our focus.
Patients benefit most when LDL‑C is aggressively lowered, risk factors are controlled, and new therapies are integrated thoughtfully as evidence evolves.
This post reflects my personal views and interpretation of recent scientific data. It is not an official Novartis communication and does not represent the position, strategy, or endorsement of my employer.”
Stay updated with Hemostasis Today.
-
Sep 27, 2026, 15:41Ahmed Hamandi: Sharing Real-World HSCT Experience at the Iraqi Society of Haematology Conference
-
Sep 27, 2026, 15:39Co-creating Digital Support With Young Stroke Survivors – European Stroke Organisation
-
Sep 27, 2026, 15:39Eleri Schiavone: Celebrating 80 Years of the Welsh Blood Service
-
Sep 27, 2026, 15:38Jessica Garcia: Standing Where VWD Was First Recognized 100 Years Later
-
Sep 27, 2026, 15:37Heghine Khachatryan: A Meaningful Step Forward for Inherited Blood Disorders in Africa
-
Sep 27, 2026, 15:07James P. Crowley: Dr Richard Silver and the Evolution of Hematology-Oncology
-
Sep 27, 2026, 14:53Why Does Plasma Form Such Robust Fibrin Clots – RPTH Journal
-
Sep 27, 2026, 14:11Sontyana Jyothi Swarupa: Dr Wolfgang Willenbacher Joins ISHBD 2027 Organising Committee
-
Sep 27, 2026, 13:58Thrombin-Trained Immunity and the Biology of Recurrent VTE